Drug Information

Drug General Information
Drug ID
D01RHR
Former ID
DIB019445
Drug Name
compound 31
Drug Type
Small molecular drug
Indication Discovery agent Investigative [532836]
Structure
Download
2D MOL
Formula
C29H23F3N6O3
InChI
InChI=1S/C29H23F3N6O3/c1-3-25(39)35-20-8-5-9-21(13-20)38-28-33-15-23(16-34-28)37-27(41)24-14-22(11-10-17(24)2)36-26(40)18-6-4-7-19(12-18)29(30,31)32/h3-16H,1H2,2H3,(H,35,39)(H,36,40)(H,37,41)(H,33,34,38)
InChIKey
BTWVWABAWDKQNJ-UHFFFAOYSA-N
PubChem Compound ID
71519693
PubChem Substance ID
163511953, 240922183, 242042219, 242648951, 249565828
Target and Pathway
Target(s) tec protein tyrosine kinase Target Info Inhibitor [532836]
BLK proto-oncogene, Src family tyrosine kinase Target Info Inhibitor [532836]
Tyrosine-protein kinase BTK Target Info Inhibitor [532836]
BMX non-receptor tyrosine kinase Target Info Inhibitor [532836]
TXK tyrosine kinase Target Info Inhibitor [532836]
KEGG Pathway NF-kappa B signaling pathway
Osteoclast differentiation
Platelet activation
B cell receptor signaling pathway
Fc epsilon RI signaling pathway
Primary immunodeficiency
PANTHER Pathway B cell activation
Pathway Interaction Database Fc-epsilon receptor I signaling in mast cells
BCR signaling pathway
FAS (CD95) signaling pathway
Class I PI3K signaling events
EPO signaling pathway
PathWhiz Pathway Fc Epsilon Receptor I Signaling in Mast Cells
Reactome MyD88:Mal cascade initiated on plasma membrane
Regulation of actin dynamics for phagocytic cup formation
DAP12 signaling
FCERI mediated Ca+2 mobilization
MyD88 deficiency (TLR2/4)
IRAK4 deficiency (TLR2/4)
RHO GTPases Activate WASPs and WAVEs
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
WikiPathways Kit receptor signaling pathway
MyD88:Mal cascade initiated on plasma membrane
Signaling by the B Cell Receptor (BCR)
DAP12 interactions
B Cell Receptor Signaling Pathway
TSLP Signaling Pathway
Regulation of toll-like receptor signaling pathway
IL-5 Signaling Pathway
References
Ref 532836Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28.
Ref 532836Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.